Overview

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

Status:
Completed

Trial end date:
2020-01-29

Target enrollment:

Participant gender:

Summary

This is a pilot, open label, single center study in 30 women undergoing breast augmentation. The study will assess and collect information on pharmacokinetics and safety of EXPAREL administered as a pectoral plane block. A total of 15 subjects will be enrolled in each of the 2 cohorts.

Phase:

Phase 1

Details

Lead Sponsor:

Pacira Pharmaceuticals, Inc

Treatments:

Bupivacaine